Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 5/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380141 | 0.78 | CTSL (0.37) | CTSLCTSBLATS1AAK1RAB9A | |
| SCHEMBL30601010 | 0.74 | MAP4K1 (0.44) | LATS1RAB9ANAMPTCYP17A1MAP4K1 | |
| SCHEMBL2154612 | 0.71 | CTSL (0.38) | CTSLCTSBAAK1MEN1KMT2A | |
| SCHEMBL30600809 | 0.70 | MAP4K1 (0.43) | CTSLCTSBNAMPTCYP17A1KMT2A | |
| SCHEMBL27141591 | 0.69 | LATS1 (0.45) | LATS1RAB9ALATS2 | |
| SCHEMBL30782353 | 0.69 | LATS1 (0.45) | LATS1RAB9ALATS2 | |
| SCHEMBL30600875 | 0.69 | MAP4K1 (0.61) | CYP17A1MAP4K1 | |
| SCHEMBL31256305 | 0.69 | TOP2A (0.50) | — | |
| SCHEMBL30752879 | 0.69 | ELANE (0.40) | NAMPT | |
| SCHEMBL12685162 | 0.67 | NR1H2 (0.39) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2545053-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCND3 | CTSL 2264/4885CTSB 1829/4885LATS1 3046/4885 |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | KCNQ3, KCNK3, KCND3 | CTSL 2264/4885CTSB 1829/4885LATS1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.